COMMITTEES - SCIENTIFIC PROGRAM AND DIGITAL CONTENT

POST MEETING INFORMATION - PARTNERS AND SPONSORS

HEP DART 2019: SCIENTIFIC PROGRAM AND DIGITAL CONTENT

Please click on each talk title to view and download PDF slides. The PDF slides are not included for speaker slides where distribution permission was not obtained.

Click Here to download Abstract book for HEP DART 2019

DAY 1: SUNDAY, DECEMBER 8, 2019

SESSION 1: Global viral hepatitis and chronic liver disease: Epidemiology and prospects for elimination

Plenary Lecture: Current landscape of NASH, HCC and viral hepatitis
View on Youtube

Robert Wong

Alameda Health Systems, USA

Controversies in chronic viral hepatitis epidemiology
View on Youtube

Robert Gish

Hepatitis B Foundation, USA

Elimination of HCV in Egypt: A global model

Manal El-Sayed

Ain Shams University, Egypt

SEARCHing for Hepatitis - the Australian conundrum

Miriam Levy

University of New South Wales, Australia

Highlights from the liver meeting, AASLD 2019
View on Youtube

Michael Fried

University of North Carolina at Chapel Hill, USA

Update on ICE-HBV activities

Peter Revill

VIDRL, Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity, Australia

DAY 2: MONDAY, DECEMBER 9, 2019

William H. Prusoff HEP DART Lifetime Achievement Award lecture: On the origin of the hepatitis B virus: Will the real “Australia Antigen” please stand up?”
View on Youtube

Stephen Locarnini

Victorian Infectious Diseases Reference Laboratory, Australia

SESSION 2: Overview of viral hepatitis and NASH

State of the Art Lecture: Chronic hepatitis B viral infection in North America: Lessons from the hepatitis B research network
View on Youtube

Adrian Di Bisceglie

Saint Louis University, USA

Colocation care model of HCV in people who inject drugs
View on Youtube

Elana Rosenthal

University of Maryland, USA

Plenary Lecture: Mechanisms of NAFLD development and therapeutic strategies
View on Youtube

Scott Friedman

Icahn School of Medicine at Mount Sinai, USA

Decoupling DAAs and HCC
View on Youtube

Marc Bourlière

Hôpital Saint Joseph, France

Global Virus Network awareness

Christian Bréchot

University of South Florida, USA

Oral Abstract Session I: New developments in nucleoside and nucleic acid polymer inhibitors of HBV.

A novel long-acting Anti-HBV nucleoside, E-CFCP, potently blocks the infectivity and replication of wild-type and drug-resistant HBVs in human-liver-chimeric mice with potential QW oral dosing schedule capabilities

Hiroaki Mitsuya

National Center for Global Health & Medicine/National Cancer Institute, Japan/ USA

ATI-2173, a novel HBV nucleoside phosphoramidate for HBV cure regimens
View on Youtube

Douglas Mayers

Antios Therapeutics, USA

Transaminase flares during HBsAg reduction to < 1 IU/mL are correlated with the establishment of functional cure of HBV following NAP-based combination therapy

Andrew Vaillant

Replicor Inc., Canada

SESSION 3: Hepatitis B basic science (Hepatitis B Foundation sponsored session)

State of the Art lecture: Molecular pathways of HBV cccDNA biosynthesis and transcription suppression by IFN-alpha
View on Youtube

Ju-tao Guo

Baruch S. Blumberg Institute of Living Science, USA

Single hepatocyte molecular analysis of HBV from paired biopsies in HIV-HBV co-infection
View on Youtube

Chloe Thio

Johns Hopkins, USA

PD-1 blockade recovers dysfunctional virus-specific B cells in chronic hepatitis B infection
View on Youtube

Antonio Bertoletti

Duke-NUS Medical School, Singapore

Occult HBV infection
View on Youtube

Teresa Pollicino

University Hospital of Messina, Italy

Therapeutic vaccination in hepatitis B

Ulrike Protzer

Institute of Virology, Technical University of Munich, Germany

SESSION 4: Betting on a hep B cure

State of the art lecture: Clinical update on drugs for HBV Cure
View on Youtube

Harry Janssen

Toronto Center for Liver Disease, University Health Network, Canada

Plenary Lecture: What would an HBV cure look like? Endpoints and clinical trial design towards a cure
View on Youtube

Anna Lok

University of Michigan, USA

Five decades of HBV research

George Lau

Humanity and Health Medical Group, Hong Kong

Oral Abstract session II: New therapeutic interventions with curative potential for HBV

Small molecule targeting of cis-acting regulatory RNAs encoded by Hepatitis B virus pre-genomic RNA and their therapeutic potential

Stuart Le Grice

National Cancer Institute, USA

A genome-wide CRISPR screen identifies ZCCHC14 as a host factor required for hepatitis B surface antigen production
View on Youtube

Anastasia Hyrina

Novartis Institutes for BioMedical Research, USA

Core components of DNA lagging strand synthesis machinery are essential for hepatitis B virus cccDNA formation
View on Youtube

Lei Wei

Princeton University, USA

DAY 3: TUESDAY, DECEMBER 10, 2019

SESSION 5: Improvements on current HBV, HCV and HCC therapy

HBV in the Hepather cohort: Are all patients treated according to guideline and is there a place for improvement with the new regimen?
View on Youtube

Marc Bourlière

Hôpital Saint Joseph, France

Modeling HBV therapies under development
View on Youtube

Alan Perelson

Los Alamos National Laboratory, USA

HBV co-infection with HIV or HCV
View on Youtube

Mark Sulkowski

Johns Hopkins University, USA

Plenary talk: Dash for NASH cure

Eduardo Martins

Allergan, USA

SESSION 6: Academic/Industry Session: Advances in therapeutics for NASH/NAFLD

Plenary Lecture: Human cell-based model systems combined with single cell RNASeq for discovery of novel liver disease therapeutics

Thomas Baumert

University of Strasbourg, France

Resmetirom (MGL-3196) for the treatment of nonalcoholic fatty liver disease (NAFLD): NASH fibrosis and NAFLD with dyslipidemia
View on Youtube

Becky Taub

Madrigal Pharmaceuticals, USA

Combination therapy for NASH

Rob Myers

Gilead Sciences, USA

Aramchol, a stearoyl CoA desaturase (SCD1) modulator: From Scientific Rationale to a Phase 3/4 Clinical Trial for NASH and Fibrosis
View on Youtube

Carol L. Brosgart

University of California San Francisco, USA

SESSION 7: Academic/Industry session on advances in therapeutics for HBV

Plenary Lecture: Eliminating residual HBV replication – A critical gateway to cure

Richard Colonno

Assembly Biosciences, USA

Where will RNAi fit in the era of finite therapies?

Bruce Given

Arrowhead Pharmaceuticals, USA

Progress toward an HBV cure combination therapy
View on Youtube

Michael Sofia

Arbutus Biopharma, USA

Combination approaches towards a functional cure for chronic hepatitis B
View on Youtube

Larry Blatt

Aligos Therapeutics, USA

A gene editing approach to eliminate hepatitis B virus in vivo with an ARCUS meganuclease evolved to prevent off target cutting
View on Youtube

Amy Rhoden Smith

Precision Biosciences, USA

Overview of Janssen’s novel combination antiviral therapies towards achieving functional cure (FC) for chronic hepatitis B (CHB)

Heather L. Davis

Janssen, Belgium

Preclinical profile of a novel, potent core inhibitor, EDP-514

Eoin Coakley

Enanta Pharmaceuticals, USA

DAY 4: WEDNESDAY, DECEMBER 11, 2019

SESSION 8: Immunity, vaccines and transplantation in the context of HBV and HCV infection

State of the Art Lecture: HBV vaccines new and old
View on Youtube

Marion Peters

AIDS Clinical Trial Group, USA

Lessons learned from HCV vaccine testing

Andrea Cox

Johns Hopkins University, USA

Antiviral therapies for HBV and HCV infection in the context of liver transplantation

Michael Manns

Hannover Medical School, Germany

Transplantation of HCV-Viremic donors into HCV-negative recipients: Conquests and cautions

Norah Terrault

University of Southern California, USA

Oral Abstract Session III: Advances in HCV control and elimination

C19orf66 is an interferon-induced inhibitor of HCV replication restricting formation of the viral replication organelle

Kinast Volker

Ruhr University Bochum, Germany

Micro-elimination of hepatitis C among people with HIV coinfection: Decreasing incidence and prevalence following a treatment scale up program

Joseph Doyle

Monash University and Burnet Institute, Australia

SESSION 9: New developments in liver disease, fibrosis and NASH

NASH therapeutics in children

Saul Karpen

Emory University, USA

Hepatic stellate cell phenotypes in NASH

David Brenner

University of California San Diego, USA

NAFLD and the heart

Laurence Sperling

Emory University, USA

SESSION 10: Illuminating new approaches to chronic liver disease

State of the Art Lecture: From liver disease to HCC - All roads lead to Rome
View on Youtube

Jake Liang

National Institutes of Health, USA

Genetic profiling and personalized medicine in HCC

Lewis Roberts

Mayo Clinic, USA

Discovery of protein signatures of NAFLD, NASH and HCC

Steve Williams

SomaLogic, USA

Viral hepatitis as a systemic disease: Extra-hepatic manifestations

Tarik Asselah

University Paris Diderot, INSERM, France

Oral Abstract Session IV: Clinical trials and animal models for fibrosis and chronic liver disease

Efficacy and safety of BMS-986263, a novel targeted lipid nanoparticle delivering HSP47 siRNA, in patients with advanced hepatic fibrosis: Part 1 week 12 - results from a phase 2 randomized, double-blind, placebo-controlled trial

Eric Lawitz

Texas Liver Institute, USA

Role of integrin αVß6 expressed in damaged epithelium in fibrotic diseases primary sclerosing cholangitis and idiopathic pulmonary fibrosis: Common expression patterns in human disease and mouse models

Adrian Ray

Morphic Therapeutic, USA